Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OTX-TKI Phase 1 in Neovascular AMD
NCT03630315Phase 1Completed
- Sponsor
- Ocular Therapeutix
- Start
- Feb 2019
- Primary completion
- Jan 2024
- Modality
- Hydrogel Systems, Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of axitinib intravitreal implant in neovascular age-related macular degeneration (NVAMD) (6 cohorts), sponsored by Ocular Therapeutix. Primary endpoint: Incidence of treatment emergent adverse events at 9 months. Started Feb 2019; status: completed.
02
Drugs
axitinib intravitreal implant
03
Conditions
neovascular age-related macular degeneration (NVAMD)
Beyond the preview
Go deeper on NCT03630315.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03630315.